Marco Pravetoni, PhD
University of Minnesota, Twin Cities

Hosted by Cody Wenthur

Vaccines and antibody-based strategies to counteract opioid use disorders and overdose.

The Pravetoni group is focused on the early- to late-stage development of vaccines and antibody-based therapeutics to reduce opioid use disorders and opioid-related overdoses. Our multidisciplinary research program integrates rational vaccine and antibody design, immunomodulators, formulation/delivery platforms, pre-clinical models, analysis of B and T cell lymphocyte repertoire, GLP/GMP studies to support regulatory approval and clinical evaluation, and ad hoc industry collaborations. Our team is currently planning Phase I clinical trials of vaccines targeting heroin and oxycodone. Strategies and platforms are applied to development of vaccines and antibodies to counteract other chemical or biological targets.